YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558)
Hong Kong
· Delayed Price · Currency is HKD 11.50
+1.10 (10.58%)
Apr 14, 2025, 4:08 PM HKT
HKG:1558 Revenue
In the year 2024, YiChang HEC ChangJiang Pharmaceutical had annual revenue of 3.72B CNY, down -40.84%. YiChang HEC ChangJiang Pharmaceutical had revenue of 1.27B in the half year ending December 31, 2024, a decrease of -48.24%.
Revenue
3.72B CNY
Revenue Growth
-40.84%
P/S Ratio
2.55
Revenue / Employee
766.05K CNY
Employees
4,861
Market Cap
10.12B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.72B | -2.57B | -40.84% |
| Dec 31, 2023 | 6.29B | 2.55B | 68.08% |
| Dec 31, 2022 | 3.74B | 2.83B | 309.83% |
| Dec 31, 2021 | 913.79M | -1.43B | -61.08% |
| Dec 31, 2020 | 2.35B | -3.88B | -62.27% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Alibaba Health Information Technology | 31.39B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
| Akeso | 2.26B |